About

Imetab

Imetab is a retinal metabolic imaging research company.

Imetab imaging helps the early detection of eye disease by producing a metabolic image of the back of the eye, based on how much oxygen is carried by the blood.

A new treatment window is opened between the metabolic eye changes and subsequent structural eye damage.

Metabolic imaging helps identify patients at an early stage of disease and help clinical decision making by allowing eye doctors to image the future.

Imetab anticipates that patients with age related macular degeneration (ARMD), diabetic retinopathy and glaucoma will benefit from the early detection of eye disease enabling timely therapy.

Our Vision

Imetab imaging aim is to help preserve sight. Our vision is to allow eye doctors to detect and diagnose pre-symptomatic eye disease. The early detection of pre-symptomatic eye disease, coupled with appropriate therapy, will help preserve sight.